Element Biosciences Raises Upsized Series E to Accelerate Global Expansion Across Genomic, Multiomic, and Clinical Research Solutions Ecosystem
Element Biosciences has announced an upsized Series E financing round, anchored by a $175 million investment from long-standing strategic backer Samsung Electronics, alongside additional participation from other undisclosed investors. The new capital infusion is set to accelerate the company’s commercialization efforts, expand its global footprint, and advance its expanding portfolio of genomic, multiomic, and clinical research technologies.
The financing marks another major milestone for Element Biosciences as it continues to scale beyond next-generation sequencing into a broader life sciences platform focused on integrated biological data generation. The company stated that the funding will also support continued innovation across its product pipeline, spanning research applications, translational science, and emerging diagnostic use cases.
Expanding a Multiomic Technology Ecosystem
The proceeds from the Series E round will be used to strengthen and commercialize Element Biosciences’ growing ecosystem of genomic and multiomic technologies. This includes flagship systems such as AVITI sequencing platform, the recently introduced high-throughput benchtop instrument VITARI system, and upcoming launches including AVITI Dx and tissue profiling capabilities on AVITI24.
These platforms are designed to enable researchers and clinicians to generate increasingly rich biological datasets, integrating genomic, transcriptomic, proteomic, spatial, and cellular information into a unified analytical framework. By expanding into multiomic workflows, Element aims to move beyond traditional sequencing into a more comprehensive understanding of biological systems.
The company also emphasized that the new funding will support the development of an open and interoperable technology architecture. This approach allows scientific institutions, pharmaceutical companies, and technology partners to build and scale their own applications on top of Element’s platforms, fostering an ecosystem-driven model similar to other modular technology industries.
Samsung Electronics Reinforces Long-Term Strategic Commitment
The largest portion of the Series E investment comes from Samsung Electronics, which has been a long-standing investor in Element Biosciences. TM Roh, President and Head of the Device eXperience (DX) Division at Samsung Electronics, highlighted the company’s continued confidence in Element’s technological direction and market potential.
He noted that Element has made substantial progress since Samsung’s initial investment, particularly in advancing both next-generation sequencing and broader multiomic capabilities. According to Roh, these innovations are expected to play a foundational role in the future of precision medicine and personalized diagnostics.
Samsung emphasized its broader strategic interest in supporting technologies that enable precision medicine at scale. The company views sequencing and multiomic analysis as critical infrastructure for the next generation of healthcare innovation, where data-driven insights can improve diagnosis, treatment selection, and patient outcomes.
Roh added that Samsung remains committed to investing in life sciences, medtech, and precision health technologies, with the long-term goal of improving global health outcomes through advanced scientific tools.
From Sequencing Platform to Integrated Biological Insights Engine
Since the launch of its first sequencing platform AVITI sequencing platform in 2022, Element Biosciences has rapidly evolved from a next-generation sequencing company into a broader life sciences technology provider. The company now positions itself as a multiomic solutions provider, enabling researchers to integrate multiple layers of biological data for deeper scientific insight.
This expansion reflects a broader trend in life sciences research, where single-modality sequencing is increasingly supplemented by multi-layered biological analysis. By combining genomic data with transcriptomic, proteomic, spatial, and cellular information, researchers can gain a more holistic understanding of disease mechanisms, cellular function, and therapeutic response.
Element’s platforms are designed to simplify and streamline these complex workflows by providing integrated systems that reduce technical barriers and increase accessibility for researchers across academia, biotechnology, pharmaceutical development, and clinical research organizations.
Global Expansion and Customer Adoption
The company also reported significant growth in its global footprint, now serving customers in more than 40 countries. Its user base spans academic research institutions, pharmaceutical companies, biotechnology firms, and clinical laboratories, reflecting broad adoption across the life sciences ecosystem.
This expansion highlights increasing demand for scalable, cost-efficient sequencing and multiomic solutions that can support both discovery research and translational applications. Element Biosciences has positioned its platforms as alternatives to legacy sequencing systems by focusing on flexibility, open architecture, and improved data quality.
The company’s strategy emphasizes accessibility and interoperability, enabling researchers to integrate its systems into existing laboratory workflows without requiring extensive infrastructure changes.
Leadership Perspective on Growth and Market Validation
Molly He, CEO and co-founder of Element Biosciences, described the Series E financing as a strong validation of the company’s long-term vision, technological progress, and execution capabilities. She emphasized that continued investor support reflects confidence in Element’s ability to differentiate itself in a competitive and rapidly evolving life sciences market.
He noted that the life sciences industry continues to face macroeconomic and funding challenges, making the successful completion of an upsized financing round particularly significant. The participation of both new and existing investors underscores belief in the company’s product roadmap and its ability to scale commercial adoption.
She further stated that the new capital will enable Element Biosciences to continue delivering transformative technologies that empower scientific discovery and improve human health outcomes.
Strengthening a Competitive Position in Genomics and Multiomics
The Series E round follows Element Biosciences’ previously announced $277 million Series D financing completed in mid-2024. The latest funding round reflects continued momentum as the company scales its commercial operations and advances its next-generation product pipeline.
The competitive landscape in genomics and multiomics is increasingly focused on integrating sequencing technologies with broader biological data analysis capabilities. Companies in this space are racing to develop platforms that can deliver higher throughput, lower cost per sample, and greater analytical depth.
Element’s approach—centered on modular, interoperable systems—positions it to compete not only as a sequencing provider but also as a broader infrastructure company for biological data generation.
Advancing Precision Medicine Through Scalable Technology
A key long-term objective of Element Biosciences is to support the advancement of precision medicine. By enabling more comprehensive biological data collection, the company aims to help researchers and clinicians better understand disease biology, identify therapeutic targets, and develop more effective treatments.
Multiomic analysis is increasingly seen as essential to this effort, particularly in complex diseases such as cancer, neurodegenerative disorders, and rare genetic conditions. Element’s technology stack is designed to make these approaches more accessible and scalable across research and clinical environments.
The upsized Series E financing for Element Biosciences, led by a major investment from Samsung Electronics, represents a significant milestone in the company’s evolution from a next-generation sequencing innovator to a comprehensive multiomic platform provider.
With funding directed toward expanding commercialization, accelerating product development, and strengthening global adoption, Element Biosciences is positioning itself at the center of the rapidly growing convergence between genomics, multiomics, and precision medicine. As the company continues to scale its platform ecosystem and broaden its applications, it aims to play a key role in shaping the future of biological research and clinical diagnostics worldwide.
About Element Biosciences, Inc.
Element Biosciences is pioneering the technologies that enable a deeper understanding of life. Our platforms capture biology in its full dimensionality—spanning genetic, molecular, and cellular insights—to unlock richer data and drive scientific breakthroughs. From foundational research, to the discoveries that help shape diagnostic and therapeutic development, Element empowers scientists to advance the frontiers of biology and impact every corner of human health.
